Now accepting nominations for the FiercePharma Marketing Awards
Applications are due Friday, September 13th. Submit your nominations today.
Valeant changed its name to Bausch Healthcare to distance itself from scandal, but one of its old strategies hasn't gone anywhere, an analyst says.
Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.
Sun's Shanghvi took a 99% pay cut last year. Dr. Reddy's copies of Copaxone and NuvaRing were rejected by the FDA. Natco eyes China amid hardship.
Roche’s targeted cancer drug Rozlytrek is officially cleared for a U.S. launch—and in not one, but two indications.
Sanofi scored a legal win to defend a 2021 patent and a 2031 patent for its top oncology med, Jevtana.
New king Humira, fast-growing Revlimid, Roche's under-attack cancer cash cows. Here are the biopharma's most successful drugs by lifetime sales till…
Debt-rating firm Moody's revised its Teva outlook from "stable" to "negative" as the company deals with multiple challenges.
Consumers love to hate Reckitt Benckiser's Mr. Mucus, according to a new study.
Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.
Pharma's second-quarter earnings season has come and gone, and we've ranked the players, from Regeneron's 20% sales hike to Teva's 8% drop.